Cargando…

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer

Detalles Bibliográficos
Autor principal:	Hakozaki, Taiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326776/ https://www.ncbi.nlm.nih.gov/pubmed/37425418 http://dx.doi.org/10.21037/tlcr-23-56

Ejemplares similares

PD-L1 expression in small cell lung cancer: should we designate it for assignment?
por: Hakozaki, Taiki
Publicado: (2021)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

Digital quantitative assessment of PD-L1 using digital spatial profiling
por: Gupta, Swati, et al.
Publicado: (2020)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
por: Shurin, Michael R., et al.
Publicado: (2022)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Que, Yi, et al.
Publicado: (2021)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
por: Abdayem, Pamela, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

PD-L1/PD-1: new kid on the “immune metabolic” block
por: Qorraj, Mirjeta, et al.
Publicado: (2017)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients
por: González-Cao, María, et al.
Publicado: (2022)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway
por: Zhang, Xu, et al.
Publicado: (2017)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
por: Dai, Meng-Yuan, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Sepsis in PD-1 light
por: Monneret, Guillaume, et al.
Publicado: (2016)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors
por: Le, Catherine T., et al.
Publicado: (2019)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bt37bjlti2lkuov1ndugrek5vj